ACADIA Pharma Rises on EU Recommendation for Daybue, Pipeline Progress

ACADIA Pharmaceuticals' stock surged after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its Rett syndrome treatment Daybue in the European Union. The company also reported strong quarterly revenue and announced progress in its Alzheimer's disease psychosis pipeline.

The CHMP's positive opinion means Daybue could become the first treatment permitted in Europe for the neurobehavioral symptoms of Rett syndrome. The recommendation is a significant regulatory milestone for the drug, which is already approved in the United States.

Following the announcement, ACADIA Pharmaceuticals' shares gained 12.2% as of 12:17 p.m. ET on Friday, pushing the stock back within sight of its 52-week high hit late last year. The company's market capitalization is less than $5 billion.

Financial results for the first quarter showed revenue of $101 million for Daybue and $167 million for Nuplazid (pimavanserin), its treatment for psychosis in Parkinson's disease and Alzheimer's. Sales of Daybue grew 20% year over year in the quarter. For the full year, the company reported US$1.10 billion in revenue and US$375.65 million in net income.

Alongside the commercial updates, ACADIA highlighted progress on its pipeline. The company is advancing remlifanserin for Alzheimer's disease psychosis, has expanded the sales force for NUPLAZID, and is rolling out a STIX formulation of DAYBUE to support patient convenience and treatment persistence.

Recent analyst commentary from major financial firms has generally leaned constructive, focusing on the durability of Nuplazid, the risk-adjusted value of the pipeline, and potential business development or strategic interest from larger players. Key factors for investors include the commercial trajectory of Nuplazid, pipeline catalysts in neuropsychiatric and rare-disease indications, and the company's cash runway to fund trials without major dilution.

ACADIA Pharmaceuticals is a U.S.-based biopharmaceutical company focused on central nervous system disorders and rare diseases. It is not diversified in the traditional sense, which makes execution critical, but also means that successful clinical and commercial outcomes can have an outsized financial impact. The company is profitable and faces little to no competition in its core rare-disease markets.

Investors should note that the positive valuation narrative hinges on successful clinical execution and reimbursement support. Any trial setbacks or weaker-than-expected uptake for key therapies could challenge the current outlook.